{"id":"tp-58314","type":"article-newspaper","title":"Larimar Therapeutics Estimates $128.7 Million in Cash at Quarter-End","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/58314","datePublished":"2026-11-16T12:30:29.000Z","dateModified":"2026-11-16T12:30:29.000Z","language":"en","abstract":"The preliminary, unaudited estimate covers cash, equivalents and marketable securities as of Sept. 30, 2026. Larimar projects its cash runway into late Q2 2027.","section":"Business","references":[]}